Myricetin prevents high molecular weight Aβ


Journal

Free radical biology & medicine
ISSN: 1873-4596
Titre abrégé: Free Radic Biol Med
Pays: United States
ID NLM: 8709159

Informations de publication

Date de publication:
01 08 2021
Historique:
received: 22 03 2021
revised: 27 04 2021
accepted: 10 05 2021
pubmed: 21 5 2021
medline: 29 6 2021
entrez: 20 5 2021
Statut: ppublish

Résumé

Excessive accumulation of amyloid β-protein (Aβ) is one of the primary mechanisms that leads to neuronal death with phosphorylated tau in the pathogenesis of Alzheimer's disease (AD). Protofibrils, one of the high-molecular-weight Aβ oligomers (HMW-Aβo), are implicated to be important targets of disease modifying therapy of AD. We previously reported that phenolic compounds such as myricetin inhibit Aβ1-40, Aβ1-42, and α-synuclein aggregations, including their oligomerizations, which may exert protective effects against AD and Parkinson's disease. The purpose of this study was to clarify the detailed mechanism of the protective effect of myricetin against the neurotoxicity of HMW-Aβo in SH-SY5Y cells. To assess the effect of myricetin on HMW-Aβo-induced oxidative stress, we systematically examined the level of membrane oxidative damage by measuring cell membrane lipid peroxidation, membrane fluidity, and cell membrane potential, and the mitochondrial oxidative damage was evaluated by mitochondrial permeability transition (MPT), mitochondrial reactive oxygen species (ROS), and manganese-superoxide dismutase (Mn-SOD), and adenosine triphosphate (ATP) assay in SH-SY5Y cells. Myricetin has been found to increased cell viability by suppression of HMW-Aβo-induced membrane disruption in SH-SY5Y cells, as shown in reducing membrane phospholipid peroxidation and increasing membrane fluidity and membrane resistance. Myricetin has also been found to suppress HMW-Aβo-induced mitochondria dysfunction, as demonstrated in decreasing MPT, Mn-SOD, and ATP generation, raising mitochondrial membrane potential, and increasing mitochondrial-ROS generation. These results suggest that myricetin preventing HMW-Aβo-induced neurotoxicity through multiple antioxidant functions may be developed as a disease-modifying agent against AD.

Identifiants

pubmed: 34015458
pii: S0891-5849(21)00307-5
doi: 10.1016/j.freeradbiomed.2021.05.019
pii:
doi:

Substances chimiques

Amyloid beta-Peptides 0
Antioxidants 0
Flavonoids 0
Peptide Fragments 0
Reactive Oxygen Species 0
amyloid beta-protein (1-42) 0
myricetin 76XC01FTOJ

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

232-244

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Atsushi Michael Kimura (AM)

Department of Pharmacology, Division of Medical Pharmacology, School of Medicine, Showa University, Tokyo, 142-8555, Japan; Pharmacological Research Center, Showa University, Tokyo, 142-8555, Japan; Department of Internal Medicine, Division of Neurology, School of Medicine, Showa University, Tokyo, 142-8666, Japan.

Mayumi Tsuji (M)

Pharmacological Research Center, Showa University, Tokyo, 142-8555, Japan. Electronic address: tsujim@med.showa-u.ac.jp.

Taro Yasumoto (T)

Department of Internal Medicine, Division of Neurology, School of Medicine, Showa University, Tokyo, 142-8666, Japan.

Yukiko Mori (Y)

Department of Internal Medicine, Division of Neurology, School of Medicine, Showa University, Tokyo, 142-8666, Japan.

Tatsunori Oguchi (T)

Department of Pharmacology, Division of Medical Pharmacology, School of Medicine, Showa University, Tokyo, 142-8555, Japan; Pharmacological Research Center, Showa University, Tokyo, 142-8555, Japan.

Yuya Tsuji (Y)

Department of Pharmacology, Division of Medical Pharmacology, School of Medicine, Showa University, Tokyo, 142-8555, Japan; Pharmacological Research Center, Showa University, Tokyo, 142-8555, Japan.

Masakazu Umino (M)

Department of Pharmacology, Division of Medical Pharmacology, School of Medicine, Showa University, Tokyo, 142-8555, Japan; Pharmacological Research Center, Showa University, Tokyo, 142-8555, Japan.

Asami Umino (A)

Department of Pharmacology, Division of Medical Pharmacology, School of Medicine, Showa University, Tokyo, 142-8555, Japan; Pharmacological Research Center, Showa University, Tokyo, 142-8555, Japan.

Toru Nishikawa (T)

Department of Pharmacology, Division of Medical Pharmacology, School of Medicine, Showa University, Tokyo, 142-8555, Japan; Pharmacological Research Center, Showa University, Tokyo, 142-8555, Japan.

Shiro Nakamura (S)

Department of Oral Physiology, School of Dentistry, Showa University, Tokyo, 142-8555, Japan.

Tomio Inoue (T)

Department of Oral Physiology, School of Dentistry, Showa University, Tokyo, 142-8555, Japan.

Yuji Kiuchi (Y)

Department of Pharmacology, Division of Medical Pharmacology, School of Medicine, Showa University, Tokyo, 142-8555, Japan; Pharmacological Research Center, Showa University, Tokyo, 142-8555, Japan.

Masahito Yamada (M)

Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Kanazawa University, Kanazawa, 920-8640, Japan.

David B Teplow (DB)

Department of Neurology, David Geffen School of Medicine at UCLA, 635 Charles E. Young Drive South, Room 445, Los Angeles, CA, 90095, USA.

Kenjiro Ono (K)

Department of Internal Medicine, Division of Neurology, School of Medicine, Showa University, Tokyo, 142-8666, Japan. Electronic address: onoken@med.showa-u.ac.jp.

Articles similaires

T-Lymphocytes, Regulatory Lung Neoplasms Proto-Oncogene Proteins p21(ras) Animals Humans

Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis.

Spencer D Shelton, Sara House, Luiza Martins Nascentes Melo et al.
1.00
DNA, Mitochondrial Humans Melanoma Mutation Neoplasm Metastasis
Psoriasis Humans Magnesium Zinc Trace Elements
Killer Cells, Natural Animals Colorectal Neoplasms Decorin Adenoviridae

Classifications MeSH